MoonLake Immunotherapeutics adds $30M from share option

Q: How many additional shares were sold under the underwriters’ option for MLTX?

Underwriters purchased an additional 1,500,000 Class A ordinary shares of MoonLake Immunotherapeutics pursuant to their over-allotment option. These shares are referred to as the Option Shares and are part of the company’s previously announced public offering of its Class A ordinary shares.

Q: How much additional capital did MoonLake Immunotherapeutics (MLTX) raise from the option exercise?

MoonLake Immunotherapeutics received $30.0 million in additional gross proceeds from the sale of the 1,500,000 Option Shares. This amount is stated before deducting underwriting discounts, commissions and offering expenses associated with the public offering.

Q: When did the issuance and sale of MoonLake’s Option Shares close?

The issuance and sale of MoonLake Immunotherapeutics’ 1,500,000 Option Shares closed on July 14, 2026. The underwriters had exercised their option to purchase these additional shares on July 10, 2026, with closing occurring four days later.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

MoonLake Immunotherapeutics reported that underwriters in its previously announced public offering exercised in full their option to purchase an additional 1,500,000 Class A ordinary shares on July 10, 2026. The sale of these Option Shares generated $30.0 million in additional gross proceeds, before underwriting discounts, commissions and offering expenses. The issuance and sale of the Option Shares closed on July 14, 2026.

Filing Explained

Completed additional-share issuance reduces existing holders’ percentage ownership; disclosed proceeds remain gross before offering costs.

The July 14, 2026 Form 8-K confirms that the underwriters’ option exercise closed through the issuance and sale of 1,500,000 additional ordinary shares, increasing the share count and reducing existing holders’ percentage ownership absent offsetting changes.

The offering also allowed certain investors to receive pre-funded warrants instead of ordinary shares; those warrants convert into shares when exercised and carry a nominal exercise price. For the closing reported here, the filing identifies the securities as Option Shares.

The filing states that the $30.0 million of additional proceeds is gross, before underwriting discounts, commissions and offering expenses, so it does not establish the net cash increase.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Option Shares sold: 1,500,000 shares Additional gross proceeds: $30.0 million Option exercise date: July 10, 2026 +1 more

4 metrics

Option Shares sold 1,500,000 shares Additional Class A ordinary shares purchased by underwriters under the option

Additional gross proceeds $30.0 million Gross proceeds from sale of the 1,500,000 Option Shares before fees and expenses

Option exercise date July 10, 2026 Date underwriters exercised in full their option to purchase Option Shares

Closing date July 14, 2026 Date the issuance and sale of the Option Shares closed

Key Terms

pre-funded warrants, public offering, gross proceeds, underwriting discounts and commissions

4 terms

pre-funded warrants financial

"in lieu of Ordinary Shares to certain investors that so choose, pre-funded warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

public offering financial

"underwriters of the previously announced public offering of Class A ordinary shares"

A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.

gross proceeds financial

"the Company received additional gross proceeds of $30.0 million from the sale"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

underwriting discounts and commissions financial

"before deducting underwriting discounts and commissions and offering expenses"

Underwriting discounts and commissions are fees paid to financial institutions that help sell new securities to investors. They act like a commission for their role in connecting companies with buyers, often reducing the amount of money the issuing company raises. For investors, understanding these costs helps gauge how much of their investment is going toward the actual securities versus fees paid to middlemen.

FAQ

What did MoonLake Immunotherapeutics (MLTX) disclose on July 14, 2026?

MoonLake Immunotherapeutics disclosed that underwriters exercised in full their option to buy 1,500,000 additional Class A ordinary shares, generating $30.0 million in additional gross proceeds, with the issuance and sale of these shares closing on July 14, 2026.

How many additional shares were sold under the underwriters’ option for MLTX?

Underwriters purchased an additional 1,500,000 Class A ordinary shares of MoonLake Immunotherapeutics pursuant to their over-allotment option. These shares are referred to as the Option Shares and are part of the company’s previously announced public offering of its Class A ordinary shares.

How much additional capital did MoonLake Immunotherapeutics (MLTX) raise from the option exercise?

MoonLake Immunotherapeutics received $30.0 million in additional gross proceeds from the sale of the 1,500,000 Option Shares. This amount is stated before deducting underwriting discounts, commissions and offering expenses associated with the public offering.

When did the issuance and sale of MoonLake’s Option Shares close?

The issuance and sale of MoonLake Immunotherapeutics’ 1,500,000 Option Shares closed on July 14, 2026. The underwriters had exercised their option to purchase these additional shares on July 10, 2026, with closing occurring four days later.

What types of securities were included in MoonLake (MLTX)’s previously announced public offering?

The previously announced public offering by MoonLake Immunotherapeutics included Class A ordinary shares and, in lieu of shares for certain investors who chose that form, pre-funded warrants to purchase Class A ordinary shares, although the underwriters’ exercised option related only to additional ordinary shares.

Who signed the MoonLake Immunotherapeutics (MLTX) report about the option exercise?

The report describing the exercise of the underwriters’ option and the resulting $30.0 million in gross proceeds was signed on behalf of MoonLake Immunotherapeutics by Matthias Bodenstedt, who is identified as the company’s Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 07/15/2026 - 06:01 AM Accepted by SEC EDGAR 07/14/2026 - 05:31 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 14, 2026

MOONLAKE IMMUNOTHERAPEUTICS

(Exact Name of Registrant as Specified in Its Charter)

Cayman Islands

001-39630

98-1711963

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

Dorfstrasse 29

6300 Zug

Switzerland

(Address of principal executive offices and Zip Code)

41 415108022

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A ordinary share, par value $0.0001 per share		MLTX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On July 10, 2026, the underwriters of the previously announced public offering of Class A ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of MoonLake Immunotherapeutics (the “Company”) and, in lieu of Ordinary Shares to certain investors that so choose, pre-funded warrants to purchase Ordinary Shares, exercised in full their option (the “Option”) to purchase an additional 1,500,000 Ordinary Shares (the “Option Shares”). As a result of the exercise of the Option, the Company received additional gross proceeds of $30.0 million from the sale of the Option Shares, before deducting underwriting discounts and commissions and offering expenses. The closing of the issuance and sale of the Option Shares occurred on July 14, 2026.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MOONLAKE IMMUNOTHERAPEUTICS

Date: July 14, 2026	By:	/s/ Matthias Bodenstedt
	Name:	Matthias Bodenstedt
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents